Madrigal jumps as Q1 revenue hits $311M on strong Rezdiffra uptake
Madrigal Pharmaceuticals shares rose after the company reported first-quarter 2026 results showing $311.34 million in revenue, driven by continued Rezdiffra uptake. Investors focused on accelerating commercial traction and pipeline timing updates despite a quarterly net loss of about $94.4 million.
1. What’s driving MDGL higher today
Madrigal Pharmaceuticals (MDGL) is moving higher after releasing first-quarter 2026 financial results and corporate updates. The quarter showed revenue of $311.34 million, reflecting continued demand for Rezdiffra (resmetirom), the company’s commercial therapy for MASH, while the company posted a quarterly net loss of roughly $94.4 million.
2. The quarter in numbers investors are trading
The headline reaction centers on revenue scale and momentum: $311.34 million in Q1 2026 revenue and a loss per share around $3.25, alongside ongoing commercialization progress for Rezdiffra. The market is treating the report as confirmation that uptake remains strong as the company expands treated-patient and prescriber penetration.
3. Pipeline and timing updates in focus
Beyond sales, investors are also trading around Madrigal’s development timeline updates. The company said an MGL-2086 (oral GLP-1) Phase 1 trial is on track to initiate in 2Q 2026, and an ervogastat/resmetirom drug-drug interaction study is on track to initiate in 4Q 2026, supporting a longer-run combination strategy alongside the current Rezdiffra franchise.
4. What to watch next
Key near-term swing factors include evidence that Rezdiffra demand continues to expand through 2026, execution against payer and access dynamics, and whether spending trends stabilize as the commercial build continues. Investors will also track initiation and readouts from the newly highlighted pipeline programs as potential catalysts for incremental value beyond the core Rezdiffra launch.